Response to Korley et al.: Progesterone Treatment Does Not Decrease Serum Levels of Biomarkers of Glial and Neuronal Cell Injury in Moderate and Severe TBI Subjects: A Secondary Analysis of the Progesterone for Traumatic Brain Injury,Experimental Clinical Treatment (ProTECT) III Trial (DOI: 10.1089/neu.2020.7072)
Restricted accessLetterFirst published online October, 2021
Response to Korley et al.: Progesterone Treatment Does Not Decrease Serum Levels of Biomarkers of Glial and Neuronal Cell Injury in Moderate and Severe TBI Subjects: A Secondary Analysis of the Progesterone for Traumatic Brain Injury,Experimental Clinical Treatment (ProTECT) III Trial (DOI: 10.1089/neu.2020.7072)
KorleyF., PaulsQ., YeattsS.D., JonesC.M.C. , Corbett-ValadeE., SilbergleitR., FrankelM., BarsanW., CahillN.D., BazarianJ.J., and WrightD.W. (2021). Progesterone treatment does not decrease serum levels of biomarkers of glial and neuronal cell injury in moderate and severe traumatic brain injury subjects: a secondary analysis of the Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment (ProTECT) III Trial. J. Neurotrauma, 2021 [Epub ahead of print: DOI: 10.1089/neu.2020.7072].
2.
SchumacherM., DenierC., OudinetJ.P., AdamsD., and GuennounR. (2016). Progesterone neuroprotection: the background of clinical trial failure. Steroid Biochem. Mol. Biol. 160, 53–66.
3.
SteinD.G. (2015). Embracing failure: What the phase III progesterone studies can teach about TBI clinical trials. Brain Inj. 29, 1259–72.
4.
HowardR.B., SayeedI., and SteinD.G. (2017). Suboptimal dosing parameters as possible factors in the negative phase III clinical trials of progesterone for traumatic brain injury. J. Neurotrauma, 34, 1915–1918.
5.
SteinD.G., SayeedI., Espinosa-GarciaC., AtifF., and SergeevaE.G. (2017). Goldstein et al.'s Secondary Analysis of Progesterone Clinical Trial for Traumatic Brain Injury Can Only Reflect the Same Trial Design Flaws: A Response to “Very Early Administration of Progesterone Does Not Improve Neuropsychological Outcomes in Subjects with Moderate to Severe Traumatic Brain Injury.”. J. Neurotrauma, 34, 2192–2193.
6.
SteinD.G. and SayeedI. (2019). Repurposing and repositioning neurosteroids in the treatment of traumatic brain injury: a report from the trenches. Neuropharmacology, 147, 66–73.
7.
SayeedI., AtifF., Espinosa-GarciaC.. W, aliB., TurnaN, YousufS., and SteinD.G. (2018). Prehospital intubation: further confounders in trial results. Prehosp. Emerg. Care, 22, 535–536.
8.
PanZ.Y., ZhaoY.H., HuangW.H., XiaoZ.Z., and LiZ.Q. (2019). Effect of progesterone administration on the prognosis of patients with severe traumatic brain injury: a meta-analysis of randomized clinical trials. Meta-Analysis Drug Des. Devel. Ther. 13, 265–273.
9.
BegemannM., LeonM., van der HornH.J., van der NaaltJ., and SommerI. (2020). Drugs with anti-inflammatory effects to improve outcome of traumatic brain injury: a meta-analysis. Sci. Rep. 10, 16179.
10.
GossC.W., HoffmanS.W., and SteinD.G. (2003) Behavioral effects and anatomic correlates after brain injury: a progesterone dose-response study. Pharmacol. Biochem. Behav. 76, 231–242.
11.
ShearD.A., GalaniR, HoffmanS.W., and SteinD.G. (2002) Progesterone protects against necrotic damage and behavioral abnormalities caused by traumatic brain injury. Exp. Neurol. 178, 59–67.
12.
GalaniR., HoffmanS.W., and SteinD.G. (2001) Effects of the duration of progesterone treatment on the resolution of cerebral edema induced by cortical contusions in rats. Restor. Neurol. Neurosci. 18, 161–166.
13.
WaliB., IshratT., WonS., SteinD.G., and SayeedI. (2014) Progesterone in experimental permanent stroke: a dose-response and therapeutic time-window study. Brain, 137, 486–502.
14.
MurphyS.J., TraystmanR.J, and HurnP.D. (2000). Progesterone exacerbates striatal stroke injury in progesterone-deficient female animals. Stroke, 31, 1173–1178.
15.
ErcoleA., ThelinE.P., HolstA., BellanderB.M., and NelsonD.W. (2016). Kinetic modelling of serum S100b after traumatic brain injury. BMC Neurol. 16, 93.
16.
BrowningM., ShearD.A., BramlettH.M., DixonC.E., MondelloS., SchmidK.E., PoloyacS.M., DietrichW.D., HayesR.L., WangK.K., PovlishockJ.T., TortellaF.C., and KochanekP.M. (2016). Levetiracetam treatment in traumatic brain injury: Operation Brain Trauma Therapy. J. Neurotrauma, 33, 581–594.
17.
ShearD.A., DixonC.E., BramlettH.M., MondelloS., DietrichW.D., Deng-BryantY., SchmidK.E., WangK.K., HayesR.L., PovlishockJ.T., KochanekP.M., and TortellaF.C. (2016). Nicotinamide treatment in traumatic brain injury: Operation Brain Trauma Therapy. J. Neurotrauma. 33, 567–580.
18.
MountneyA., BramlettH.M., DixonC.E., MondelloS., DietrichW.D., WangK.K.W., CaudleK., EmpeyP.E., PoloyacS.N., HayesR.L., PovlishockJ.T., TortellaF.C., KochanekP.M., and ShearD.A. (2016). Simvastatin treatment in traumatic brain injury: Operation Brain Trauma Therapy. J. Neurotrauma. 33, 567–580.
19.
BramlettH.M., DietrichW.D., DixonC.E., ShearD.A., SchmidK.E., MondelloS., WangK.K., HayesR.L., PovlishockJ.T., TortellaF.C., and KochanekP.M. (2016). Erythropoietin treatment in traumatic brain injury: Operation Brain Trauma Therapy. J. Neurotrauma. 33, 538–552.
20.
DixonC.E., BramlettH.M., DietrichW.D., ShearD.A., YanH.Q., Deng-BryantY., MondelloS., WangK.K., HayesR.L., EmpeyP.E., PovlishockJ.T., TortellaF.C., and KochanekP.M. (2016). Cyclosporine treatment in traumatic brain injury: Operation Brain Trauma Therapy. J. Neurotrauma, 33, 553–566.
21.
RodneyT., OsierN., and GillJ. (2018). Pro- and anti-inflammatory biomarkers and traumatic brain injury outcomes: a review. Cytokine. 110, 248–256.
22.
GibsonC., ConstantinD., PriorM.J.W., BathP., and MurphyS.P. (2005). Progesterone supresses the inflammatory response and nitric oxide synthase-2 expression following cerebral ischemia. Exp. Neurol. 193, 522–530.
23.
CekicM., CutlerS.M., VanLandinghamJ.W., and SteinD.G. (2011). Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats. Neurobiol. Aging. 32(5), 864–874.
24.
HuaF., WangJ., IshratT., WeiW., AtifF., SayeedI., and SteinD.G. (2011). Genomic profile of Toll-like receptor pathways in traumatically brain-injured mice: effect of exogenous progesterone. J. Neuroinflammation. 8, 42.
25.
WangZ., ZuoG., ShiX.Y., ZhangJ., FangQ., and ChenG. (2011). Progesterone administration modulates cortical TLR4/NF-κB signaling pathway after subarachnoid hemorrhage in male rats. Mediators Inflamm. 2011, 848309.
26.
YousufS., AtifF., SayeedI., WangJ., and SteinD.G. (2013). Post-stroke infections exacerbate ischemic brain injury in middle-aged rats: immunomodulation and neuroprotection by progesterone. Neuroscience, 239, 92–102.
27.
SinhaS., RahejaA., SamsonN., BhoiS., SelviA., SharmaP., and SharmaB.S. (2016). Blood mitochondrial enzymatic assay as a predictor of long-term outcome in severe traumatic brain injury. J. Clin. Neurosci. 30, 31–38.
28.
RobertsonC.L., PuskarA., HoffmanG.E., MurphyA.Z., SaraswatiM., and FiskumG. (2006). Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. Exp. Neurol. 197, 235–43.
29.
RobertsonC.L. and SaraswatiM. (2015). Progesterone protects mitochondrial function in a rat model of pediatric traumatic brain injury. J. Bioenerg. Biomembr. 47, 43–51.
30.
ClausenF. (2012). Interstitial F2-isoprostane 8-Iso-PGF2α as a biomarker of oxidative stress after severe human traumatic brain injury. J. Neurotrauma, 29, 766–775.
31.
YuG.F., JieY.Q., WuA., HuangQ., DaiW.M., and FanX.F. (2013). Increased plasma 8-iso-prostaglandin F2α concentration in severe human traumatic brain injury. Clin. Chim. Acta. 421, 7–11.
32.
RoofR.L., HoffmanS.W., and SteinD.G. (1997). Progesterone protects against lipid peroxidation following traumatic brain injury in rats. Mol. Chem. Neuropathol. 31, 1–11
33.
AgrafiotisD.K., YangE., LittmanG.S., ByttebierG., DipietroL., DiBernardoA., ChavezJ.C., RykmanA., McArthurK., HajjarK., LeesK.R., VolpeB.T., KramsM., and KrebsJ.I. (2021). Accurate prediction of clinical stroke scales and improved biomarkers of motor impairment from robotic measurements. PLoS One. 16, e0245874.
34.
FrankelM., FanL., YeattsS.D., JerominA., VosP.E., WagnerA.K., WolfB.J., PaulsQ., LunneyM., MerckL.H., HallC.L., PaleschY.Y., SilbergleitR., and WrightD.W. (2019). Association of very early serum levels of S100B, glial fibrillary acidic protein, ubiquitin c-terminal hydrolase-l1, and spectrin breakdown product with outcome in ProTECT III. J Neurotrauma, 36, 2863–2871.
